CLN Celon Pharma S.A.

3.888USD15.64 PLN · GPW+0.90%Mkt Cap: 209.62M USDP/E: 7.67

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, …

Key Statistics

Company
Market Cap209.62M USD
Enterprise Value232.75M USD
Revenue (TTM)64.05M USD
Gross Profit49.14M USD
Net Income (TTM)-19.73M USD
Revenue/Share1.22 USD
Last Price3.888 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees560
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINPLCLNPH00015
Valuation
P/E (Trailing)7.67
P/E (Forward)9.78
PEG—
EV/EBITDA39.22
EV/Revenue3.63
P/S3.27
P/B2.32
EPS (TTM)0.51 USD
EPS (Forward)0.40 USD
52W Range
3.7795% of range5.842
52W High5.842 USD
52W Low3.779 USD
Profitability
Gross Margin76.71%
Oper. Margin-1.90%
EBITDA Margin9.27%
Profit Margin41.46%
ROE-21.85%
ROA-17.35%
ROIC—
ROCE-6.31%
Growth
Revenue Growth-0.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF5.93M USD
CapEx (TTM)—
FCF Margin-19.13%
FCF Yield-5.85%
Net Debt23.35M USD
Net Debt/EBITDA3.93
Net Debt/FCF—
Balance Sheet
Debt/Equity25.76
Current Ratio1.76
Quick Ratio1.38
Book Value/Sh1.68 USD
Cash/Share0.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield0.29%
Payout Ratio0.00%
Ex-Div DateJun 27, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.067 USD
Upside (mean)+30.3%
Target Range3.978 USD – 6.265 USD
3.978+30.3% to mean6.265
# Analysts5
Ownership
Shares Out.53.91M
Float23.82M
Insiders55.70%
Institutions18.27%
Technical
SMA 504.648 (-16.3%)
SMA 2005.093 (-23.7%)
Beta0.60
S&P 52W Chg12.00%
Avg Vol (30d)31.91K
Avg Vol (10d)35.38K
Technical Indicators
RSI (14)26.6
MACD-0.9370
MACD Signal-0.8799
MACD Hist.-0.0571
BB Upper4.804 USD
BB Middle4.206 USD
BB Lower3.607 USD
BB Width28.47%
ATR (14)0.1887 USD
Vol Ratio (20d)0.71x

About Celon Pharma (WSE: CLN)

›

Celon Pharma (WSE: CLN) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 560 employees.

The shares were at 15.64 PLN on 19 November 2026, down 27.9% over 52 weeks. Its 52-week range is 15.20 PLN to 23.50 PLN: the price is 33.4% below the high and 2.9% above the low.

At a market capitalisation of 843.18M PLN, it trades at 7.7 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 69% for CLN.

Celon Pharma reports return on equity of -21.8%, an operating margin of -1.9% and flat revenue year over year.

Its debt exceeds its cash by 93.91M PLN. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock; their mean price target of 20.38 PLN is 30.3% above the current price.